Viaskin peanut skin patch ‘does cure allergy’ finds study
- The Viaskin peanut skin patch increased resilience 10-fold compared to a placebo in a phase 2b trial, a new study claims
- The patch gradually exposes patients to the proteins that trigger a reaction
- Last month, a study said the patch worked no better than a placebo in kids
- But this study says it is more effective if it administers a high dose of the protein
Mia De Graaf For Dailymail.com
47
View
comments
A simple patch could cure life-threatening peanut allergies, new research claims.
Viaskin Peanut is a stick-on band designed to gradually expose patients to the proteins that give them an allergic reaction.
Last month, the so-called ‘vaccine’ failed in a large clinical trial, faring no better than a placebo.
However, researchers at the Icahn School of Medicine in New York insists it should not be ruled out just yet, since their trial found the patch left patients 10 times more resilient.
Viaskin Peanut is a stick-on band designed to gradually expose patients to the protein that give them an allergic reaction. A new study found it increases resilience 10-fold
The phase 2b trial – one of the latest stages before it can be approved for the market – involved 221 people with peanut allergies aged between six and 55 years old.
For two years, a quarter of the patients were treated with a placebo, while the other three-quarters received one of three strengths of the skin patch.
They were assessed every 12 months by receiving incremental doses of peanut to monitor their reaction.
-
Just one traumatic event increases a woman’s risk of obesity…
‘It’s a patient’s worst paranoia’: FDA approves first ever…
Those who received the strongest patch were 10 times more resilient than those who received the placebo, according to the report published in the Journal of American Medical Association (JAMA) today.
There was no difference between the placebo and the two weaker strengths.
Lead author Dr Hugh Sampson said the results show that the patch is effective if it administers a high dose, despite fears that it flopped in previous trials.
Last month, a report revealed the patch was no more effective for 300 child patients than a placebo.
However, manufacturer DBV Technologies, who plan to trade the patch under the name Viaskin, already had Dr Sampson’s data and insisted they still planned to move towards filing for FDA approval.
A spokesman said the FDA even encouraged them to proceed with trials and applications based on provisional data.
Share or comment on this article
- Wildlife park worker, 37, is left with deadly illness…
- Hot-air balloon pilot whose clients include Emma Watson…
- Pilot who flew Benedict Allen out of the jungle he had…
- Star in your own Howards End drama: For £3.95million, the…
- Relatives of victims of the King’s Cross fire which…
- Hero spy who founded Bletchley Park codebreaking unit…
- Man in his twenties suffers serious injuries after…
- Latest High Street LEND! Fashion firm targets ‘Generation…
- There’s no tyre-ing him out! Lion shows off its strength…
- Police chief vows to stop arresting drug addicts and ‘low…
- Hospital of hope: Unprecedented access to a 12-hour shift…
- ‘He hasn’t shown an ounce of remorse’: Father of…
- Memo to Gove and Boris… Your letter to the PM was…
- ‘Drunk’ Labour MP ‘went berserk and unleashed…
- Retired British solicitor, 60, dies at sea after falling…
- The oldest restaurant in Europe is still going in the…
- À la farce! Two Michelin star restaurant in a quaint…
- Hammond woos Millennials with £5bn Budget vow to build…
Comments 47
Share what you think
-
Newest -
Oldest -
Best rated -
Worst rated
The comments below have not been moderated.
The views expressed in the contents above are those of our users and do not necessarily reflect the views of MailOnline.
We are no longer accepting comments on this article.